Echocardiographic findings following renal sympathetic denervation for treatment resistant hypertension, the ReShape CV-risk study

References

• Collaborators GBDRF. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1–11. doi: 10.1016/S0140-6736(20)30752-2.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the european society of cardiology and the european society of hypertension. Blood Press. 2018;27(6):314–340. doi: 10.1080/08037051.2018.1527177.
   PubMed Web of Science ®Google Scholar
• Raman SV. The hypertensive heart. An integrated understanding informed by imaging. J Am Coll Cardiol. 2010;55(2):91–96. doi: 10.1016/j.jacc.2009.07.059.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21(5):500–508. doi: 10.1038/ajh.2008.16.
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med. 1990;322(22):1561–1566. doi: 10.1056/NEJM199005313222203.
   PubMed Web of Science ®Google Scholar
• Fagard RH, Celis H, Thijs L, et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54(5):1084–1091. doi: 10.1161/HYPERTENSIONAHA.109.136655.
   PubMed Web of Science ®Google Scholar
• Brooks JE, Soliman EZ, Upadhya B. Is left ventricular hypertrophy a valid therapeutic target? Curr Hypertens Rep. 2019;21(6):47. doi: 10.1007/s11906-019-0952-9.
   PubMed Web of Science ®Google Scholar
• Pierdomenico SD, Cuccurullo F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens. 2010;23(8):876–881. doi: 10.1038/ajh.2010.80.
   PubMed Web of Science ®Google Scholar
• Cramariuc D, Gerdts E. Epidemiology of left ventricular hypertrophy in hypertension: implications for the clinic. Expert Rev Cardiovasc Ther. 2016;14(8):915–926. doi: 10.1080/14779072.2016.1186542.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick JN, Vannan MA, Narula J, et al. Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol. 2007;50(5):381–396. doi: 10.1016/j.jacc.2007.03.048.
   PubMed Web of Science ®Google Scholar
• Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the european association of cardiovascular imaging (EACVI) and the American society of echocardiography (ASE)dagger. Eur Heart J Cardiovasc Imaging. 2015;16(6):577–605.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, D’Agostino RB, Belanger AJ, et al. Left atrial size and the risk of stroke and death. The framingham heart study. Circulation. 1995;92(4):835–841. doi: 10.1161/01.cir.92.4.835.
   PubMed Web of Science ®Google Scholar
• Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124–1140. doi: 10.1161/CIRCRESAHA.118.313220.
   PubMed Web of Science ®Google Scholar
• Wei FF, Zhang ZY, Huang QF, et al. Resistant hypertension. Kardiol Pol. 2018;76(7):1031–1042. doi: 10.5603/KP.a2018.0129.
   PubMed Web of Science ®Google Scholar
• Sata Y, Head GA, Denton K, et al. Role of the sympathetic nervous system and its modulation in renal hypertension. Front Med (Lausanne). 2018;5:82. doi: 10.3389/fmed.2018.00082.
   PubMed Web of Science ®Google Scholar
• Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976–990. doi: 10.1161/CIRCRESAHA.116.303604.
   PubMed Web of Science ®Google Scholar
• Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–1965. doi: 10.1016/S0140-6736(14)61942-5.
   PubMed Web of Science ®Google Scholar
• Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–2170. doi: 10.1016/S0140-6736(17)32281-X.
   PubMed Web of Science ®Google Scholar
• Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–2345. doi: 10.1016/S0140-6736(18)31082-1.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–2355. doi: 10.1016/S0140-6736(18)30951-6.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Mahfoud F, Mancia G, et al. European society of hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733–1741. doi: 10.1097/HJH.0000000000002933.
   PubMed Web of Science ®Google Scholar
• Barbato E, Azizi M, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC council on hypertension and the european association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J. 2023;44(15):1313–1330. doi: 10.1093/eurheartj/ehad054.
   PubMed Web of Science ®Google Scholar
• Feyz L, van Dalen BM, Geleijnse ML, et al. Effect of catheter-based renal denervation on left ventricular function, mass and (un)twist with two-dimensional speckle tracking echocardiography. J Echocardiogr. 2017;15(4):158–165. doi: 10.1007/s12574-017-0336-6.
   PubMedGoogle Scholar
• McLellan AJ, Schlaich MP, Taylor AJ, et al. Reverse cardiac remodeling after renal denervation: atrial electrophysiologic and structural changes associated with blood pressure lowering. Heart Rhythm. 2015;12(5):982–990. doi: 10.1016/j.hrthm.2015.01.039.
   PubMed Web of Science ®Google Scholar
• Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901–909. doi: 10.1016/j.jacc.2011.11.034.
   PubMed Web of Science ®Google Scholar
• Schirmer SH, Sayed MM, Reil JC, et al. Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol. 2014;63(18):1916–1923. doi: 10.1016/j.jacc.2013.10.073.
   PubMed Web of Science ®Google Scholar
• Miroslawska A, Solbu M, Skjølsvik E, et al. Renal sympathetic denervation: effect on ambulatory blood pressure and blood pressure variability in patients with treatment-resistant hypertension. The ReShape CV-risk study. J Hum Hypertens. 2016;30(3):153–157. doi: 10.1038/jhh.2015.69.
   PubMed Web of Science ®Google Scholar
• Perrone-Filardi P, Coca A, Galderisi M, et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus paper from the european association of cardiovascular imaging (EACVI), the european society of cardiology council on hypertension, and the european society of hypertension (ESH). Eur Heart J Cardiovasc Imaging. 2017;18(9):945–960. doi: 10.1093/ehjci/jex094.
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the european association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–270. doi: 10.1093/ehjci/jev014.
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the european association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2016;17(12):1321–1360. doi: 10.1093/ehjci/jew082.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640–1645. doi: 10.1161/CIRCULATIONAHA.109.192644.
   PubMed Web of Science ®Google Scholar
• Lu D, Wang K, Wang S, et al. Beneficial effects of renal denervation on cardiac angiogenesis in rats with prolonged pressure overload. Acta Physiol (Oxf). 2017;220(1):47–57. doi: 10.1111/apha.12793.
   PubMed Web of Science ®Google Scholar
• Carlstrom M. Therapeutic value of renal denervation in cardiovascular disease? Acta Physiol (Oxf). 2017;220(1):11–13. doi: 10.1111/apha.12816.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Iwanaga Y, Miyaji Y, et al. Renal denervation mitigates cardiac remodeling and renal damage in dahl rats: a comparison with beta-receptor blockade. Hypertens Res. 2016;39(4):217–226. doi: 10.1038/hr.2015.133.
   PubMed Web of Science ®Google Scholar
• Linz D, Hohl M, Schütze J, et al. Progression of ­kidney injury and cardiac remodeling in obese ­spontaneously hypertensive rats: the role of renal ­sympathetic innervation. Am J Hypertens. 2015;28(2):256–265. doi: 10.1093/ajh/hpu123.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao Q, Huang H, et al. Effect of renal sympathetic denervation on atrial substrate remodeling in ambulatory canines with prolonged atrial pacing. PLoS One. 2013;8(5):e64611. doi: 10.1371/journal.pone.0064611.
   PubMed Web of Science ®Google Scholar
• Li ZZ, Jiang H, Chen D, et al. Renal sympathetic denervation improves cardiac dysfunction in rats with chronic pressure overload. Physiol Res. 2015;64(5):653–662.
   PubMed Web of Science ®Google Scholar
• Peleli M, Al-Mashhadi A, Yang T, et al. Renal denervation attenuates NADPH oxidase-mediated oxidative stress and hypertension in rats with hydronephrosis. Am J Physiol Renal Physiol. 2016;310(1):F43–56. doi: 10.1152/ajprenal.00345.2015.
   PubMed Web of Science ®Google Scholar
• Kordalis A, Tsiachris D, Pietri P, et al. Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis. J Hypertens. 2018;36(8):1614–1621. doi: 10.1097/HJH.0000000000001798.
   PubMed Web of Science ®Google Scholar
• Ewen S, Ukena C, Linz D, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension. 2015;65(1):193–199. doi: 10.1161/HYPERTENSIONAHA.114.04336.
   PubMed Web of Science ®Google Scholar
• Oliveras A, Armario P, Sans L, et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (denervacion en hipertension arterial) study. J Clin Hypertens (Greenwich). 2018;20(1):69–75. doi: 10.1111/jch.13156.
   PubMed Web of Science ®Google Scholar
• Rosa J, Widimský P, Waldauf P, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-Year outcomes of randomized PRAGUE-15 study. Hypertension. 2016 Feb;67(2):397–403. doi: 10.1161/HYPERTENSIONAHA.115.06526.
   PubMed Web of Science ®Google Scholar
• Maugeri A, Hruskova J, Jakubik J, et al. Independent effects of hypertension and obesity on left ventricular mass and geometry: evidence from the cardiovision 2030 study. J Clin Med. 2019;8(3):370. doi: 10.3390/jcm8030370.
   PubMed Web of Science ®Google Scholar
• Miroslawska AK, Gjessing PF, Solbu MD, et al. Renal denervation for resistant hypertension fails to improve insulin resistance as assessed by Hyperinsulinemic-Euglycemic step clamp. Diabetes. 2016;65(8):2164–2168. doi: 10.2337/db16-0205.
   PubMed Web of Science ®Google Scholar
• Mancusi C, Izzo R, di Gioia G, et al. Insulin resistance the hinge between hypertension and type 2 diabetes. High Blood Press Cardiovasc Prev. 2020;27(6):515–526. doi: 10.1007/s40292-020-00408-8.
   PubMed Web of Science ®Google Scholar
• de Simone G, Mancusi C, Izzo R, et al. Obesity and hypertensive heart disease: focus on body composition and sex differences. Diabetol Metab Syndr. 2016;8(1):79. doi: 10.1186/s13098-016-0193-x.
   PubMedGoogle Scholar
• Sciacqua A, Cimellaro A, Mancuso L, et al. Different patterns of left ventricular hypertrophy in metabolically healthy and insulin-resistant obese subjects. Nutrients. 2020;12(2):412. doi: 10.3390/nu12020412.
   PubMed Web of Science ®Google Scholar
• de Sousa Almeida M, de Araujo Goncalves P, Branco P, et al. Impact of renal sympathetic denervation on left ventricular structure and function at 1-year follow-up. PLoS One. 2016;11(3):e0149855. doi: 10.1371/journal.pone.0149855.
   PubMed Web of Science ®Google Scholar
• Solbu MD, Miroslawska A, Norvik JV, et al. Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The reshape CV-risk study. J Clin Hypertens (Greenwich). 2021;23(5):954–962. doi: 10.1111/jch.14214.
   PubMed Web of Science ®Google Scholar
• Miroslawska AK, Gjessing PF, Solbu MD, et al. Metabolic effects two years after renal denervation in insulin resistant hypertensive patients. The re-shape CV-risk study. Clin Nutr. 2021;40(4):1503–1509. doi: 10.1016/j.clnu.2021.02.027.
   PubMed Web of Science ®Google Scholar